November 19, 2019
  • November 19, 2019
Breaking News
  • Home
  • Health
  • Bristol-Myers Squibb Company (NYSE:BMY) provided update on approval process with Celgene Corporation

Bristol-Myers Squibb Company (NYSE:BMY) provided update on approval process with Celgene Corporation

By on June 25, 2019 0

Bristol-Myers Squibb Company (NYSE:BMY) provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation. The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTC”) on the FTC’s continued review of the proposed transaction. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).

Bristol-Myers Squibb Company (NYSE:BMY), a Healthcare sector firm, traded 36.53 Million shares in last trading session with closing price of $45.68 per share. Company gross margin stands at 71.10% whereas its return on investment (ROI) is 25.40%. Stock value has moved between $44.35 – 63.44 in last one year. Analyst’s mean target price for Bristol-Myers Squibb Company (NYSE:BMY) is $56.10 while analysts mean recommendation is 2.30. BMY EPS growth this year is 28.70%. 

On last trading day, TKK Symphony Acquisition Corporation (NASDAQ:TKKS) shares closed at $10.04 per share. TKKS market capitalization is 69.47. Its weekly performance is 0.40% while year to date (YTD) performance is 4.04%. 

In last session MDJM Ltd. (NASDAQ:MDJH) traded 3537 shares and was closed at $2.52. Company is -68.10% away from its 52 week high and is moving 26.00% ahead of its 52 week low. MDJM Ltd. (NASDAQ:MDJH) quarterly performance is -33.68% while its price to sale ratio is 14.64. 

Freeport-McMoRan Inc. (NYSE:FCX), a Basic Materials sector firm, traded 14.26 Million shares on last trading day with closing price of $11.34 per share. Company gross margin stands at 23.10% whereas its return on investment (ROI) is 17.40%. Stock value has moved between $9.45 – 18 in last one year. Analyst’s mean target price for Freeport-McMoRan Inc. (NYSE:FCX) is $14.50 while analysts mean recommendation is 2.70. FCX EPS growth this year is 82.90%. 

Leave a comment